The Prostate Cancer Charity expresses disappointment at the
National Institute of Clinical Excellence's (NICE) decision to
reverse its recommendation that denosumab be made available on the
NHS in England and Wales to help minimise the risk of complications
once prostate cancer has spread to a man's bones.
Owen Sharp, Chief Executive of The Prostate Cancer Charity said:
"It is extremely disappointing that NICE has reversed its
recommendation to provide men with very advanced prostate cancer a
drug that can help prevent painful complications. Although we
understand the technical reasons for this decision, we would
nevertheless urge NICE to revisit its clinical guidance for men
with advanced prostate cancer to ensure they are able to access
treatments that can improve their quality of life as they approach
the end of their life."